Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Lilly

New Alzheimer’s drug slows cognitive decline by 35%, trial results show

Donanemab is second drug in a year to succeed in trials in what could be ‘beginning of the end’ of disease

The Guardian - UK

Eli Lilly says experimental drug slows Alzheimer's worsening

Eli Lilly and Co. says its experimental Alzheimer's drug appears to slow worsening of the mind-robbing disease

The Independent UK

Dow Jones Futures: Fed Hike Due, PacWest, AMD In Focus. Eli Lilly Drug Slows Alzheimer's.

Another rate hike is expected today, but Fed guidance will be key. PacWest rebounded while AMD tumbled. Eli Lilly jumped on its Alzheimer's drug.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Lilly Has Plans For Possible Anti-Obesity Medication. Here's How To Make Money With LLY Options

This trade is a neutral to bullish position and anticipates the stock holding above 390 over the summer term.

Investors Business Daily

New weight loss drug helping people lose 2.5 stone is 'coming to the UK'

A weekly injection of tirzepatide has seen people with obesity and diabetes lose over 15 percent of their bodyweight.

Daily Record

Weight loss jab that can help patients shed two-and-a-half stone set for UK approval

Tirzepatide could be given to patients with diabetes or heat disease

The Independent UK

Eli Lilly Unveils New Obesity Data As Mounjaro Blows Past Sales Estimates

Eli Lilly stock surged Thursday after diabetes drug Mounjaro blew past sales projections and led to promising weight loss in a Phase 3 study.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Good Luck Paying for Those $10,000 Obesity Drugs Everyone’s Talking About

Ozempic, Wegovy and Mounjaro can cause dramatic weight loss, and could create a market worth $150 billion a year.

Businessweek

Novo Nordisk Sinks As Eli Lilly Plots Its Showdown In Obesity

Novo Nordisk stock dipped Monday after Eli Lilly posted the details of its study comparing Mounjaro and Wegovy in obesity treatment.

Investors Business Daily

Why EV conversions could become more mainstream for classic cars through to 4WD utes

From classic cars to 4WD utes, Noah Wasmer wants EV conversions to become mainstream.

ABC News

Novo Hits Another Record High As WHO Considers A Key Move In Obesity

The World Health Organization will consider adding obesity treatments to its "essential medicines list." The move could help some drug stocks.

Investors Business Daily

Novartis Surges As It Goes After Eli Lilly's Second Biggest Moneymaker

Novartis stock surged Monday after the company's treatment reduced the risk of relapse in patients with early-stage breast cancer.

Investors Business Daily

Michael Hiltzik: Eli Lilly is slashing insulin prices, but hold your applause

Eli Lilly & Co. played the altruism card like a champ on Mar. 1, when it announced steep price cuts on its insulin products of as much as 70%.

Los Angeles Times

Novo Nordisk will cut some U.S. insulin prices by up to 75% starting next year

The Danish drugmaker's move follows a similar announcement by rival Eli Lilly earlier this month. More than 8 million Americans use insulin, according to the American Diabetes Association.

WEKU

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Novo Nordisk to slash insulin price by up to 75% in push for affordable diabetes treatments

The brand is the latest to plan dramatic price cuts for the diabetes drug

Tribune News Service

Why does insulin cost so much? Big Pharma isn’t the only player driving prices

Eli Lilly & Co.’s announcement that it is slashing prices for its major insulin products could make life easier for some diabetes patients while easing pressure on Big Pharma.

Inverse

This Essential Medical Treatment Could Finally Become Affordable For Everyone

Pharmaceutical giant Eli Lilly is slashing the list prices for some of its most popular insulin products by 70 percent.

Investors Business Daily

Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed

Eli Lilly stock and Biogen stock diverged Thursday after Lilly said a decade-long study of an Alzheimer's treatment definitively failed.

Get all your
news in one place.

100’s of premium titles.
One news app.

Miami Herald

$35 for insulin? What to know about Eli Lilly’s price slash for the diabetic medicine

Eli Lilly plans to slash the cost of some of its most popular insulin drugs later this year for people with and without insurance, in a move that could make the lifesaving medication more affordable for some patients living with diabetes.

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

When Mounjaro came on the market, TikTok went wild. People with obesity ordered the drug in droves thanks to a coupon that allowed them to access it for just $25 a month. Then the coupon went away, leaving destruction in its wake — and obese patients warring with diabetics. Emily…

Tribune News Service

Editorial: What insulin should cost: Eli Lilly comes through for Americans with diabetes

A hearty thank you to Eli Lilly, one of the planet’s top three producers of insulin, for slashing the price of its most widely prescribed form of insulin by 70% while capping related out-of-pocket costs at $35 a month. That means diabetics with private insurance will now pay costs on…

The Conversation

Eli Lilly is cutting insulin prices and capping copays at $35 – 5 questions answered

Pharmaceutical giant Eli Lilly is slashing the list prices for some of its most popular insulin products by 70% and capping insulin copays at US$35 for uninsured patients and those with private health insurance. These changes follow efforts by the federal government, the California state government, nonprofits and some companies…

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

Tribune News Service

Eli Lilly is capping consumer insulin costs at $35

Eli Lilly & Co. is capping out-of-pocket costs for insulin at $35 a month, following a public plea from President Joe Biden for lower prices of the diabetes treatment for all Americans.

Al Jazeera

US drug maker to slash some insulin prices, expand cost cap

President Joe Biden hails move by Eli Lilly as a ‘big deal’, calling on other manufacturers to also reduce prices.

1 … 9 10 11 12

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.